10don MSN
Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns
July 10 (Reuters) - Elevar Therapeutics and Hengrui suffered a fresh setback on Friday after the U.S. FDA declined to approve ...
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
July 10 (Reuters) - Elevar Therapeutics said on Friday that the U.S. FDA declined to approve its drug combination for a type ...
Editor's Note: Since this story's original publication on July 10, Elevar has adjusted its expected refile timeline and the story has been updated to reflect that. After a meeting with the FDA last ...
FORT LEE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating ...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, ...
The MarketWatch News Department was not involved in the creation of this content. FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., ...
FORT LEE, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully integrated biopharmaceutical company dedicated to elevating treatment ...
First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, Florida Global multi-site study includes locations in U.S., Korea, the UK, Spain, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results